TERT Promoter Mutations Are an Independent Predictor of Distant Metastasis in Middle Eastern Papillary Thyroid Microcarcinoma

Papillary thyroid microcarcinomas (PTMCs) have been attributed to the recent increased incidence of thyroid cancer. Although indolent, a subset of PTMC could potentially develop distant metastasis (DM). This study aimed to evaluate the clinico-pathological features and molecular characteristics of P...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) Vol. 13; p. 808298
Main Authors: Parvathareddy, Sandeep Kumar, Siraj, Abdul K, Iqbal, Kaleem, Qadri, Zeeshan, Ahmed, Saeeda O, Al-Rasheed, Maha, AlQatie, Ahmed A, Al-Sobhi, Saif S, Al-Dayel, Fouad, Al-Kuraya, Khawla S
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 11-03-2022
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Papillary thyroid microcarcinomas (PTMCs) have been attributed to the recent increased incidence of thyroid cancer. Although indolent, a subset of PTMC could potentially develop distant metastasis (DM). This study aimed to evaluate the clinico-pathological features and molecular characteristics of PTMC and identify the risk factors for DM in PTMC patients from Middle Eastern ethnicity. We retrospectively analyzed 210 patients with histologically confirmed PTMC. Clinico-pathological associations for DM, mutation and mutation were analyzed successfully in 184 patients. Multivariate analysis was performed using Cox proportional hazards model and logistic regression analysis. Among the PTMC patients included in this cohort, DM was noted in 6.0% (11/184), whereas tumor relapse occurred in 29/184 (15.8%). Of the 11 cases with DM, lung metastasis occurred in 8 cases, bone metastasis in 2 cases and brain metastasis in 1 case. Presence of extrathyroidal extension and male sex were significantly associated with DM. Molecular analysis showed mutations to be the most frequent, being detected in 45.7% (84/184). promoter mutations were detected in 16 (8.7%) cases and were significantly associated with DM and shorter metastasis-free survival in multivariate analysis. Our study indicates a surprisingly high frequency of promoter mutation in Saudi patients with PTMC. Identifying promoter mutations as an independent predictor of DM in patients with microcarcinoma could explain the inherent aggressive nature of PTMC from Middle Eastern ethnicity and magnify its role in patient risk stratification, which might help in improving therapeutic strategy for these patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Paula Soares, Universidade do Porto, Portugal; Simona Censi, University of Padua, Italy
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology
These authors have contributed equally to this work
Edited by: Jing Yang, Sichuan University, China
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.808298